Kabasura Kudineer helps check Covid-19, claims study

Sri Ravishankar’s Tattva has launched a classical Siddha medicine, Kabasura Kudineer, which it claims helps in the prevention and treatment of coronavirus. Under the guidance of Germany-based Frankfurt Innovation Center for Biotechnology, the company tested the drug combination for anti-inflammatory and immune-boosting Ayurvedic agents and their effectiveness against the novel coronavirus. A research study by Frankfurt Innovation Center for Biotechnology (FIZ) shows the efficacy of Kabasura Kudineer tablet, along with other Ayurveda medicines, for screening inhibitors of the SARS-COV-2 Spike: ACE2 interaction. The study found that Kabasuraa Kudineer tablets were the strongest inhibitor (84%) of Spike glycoprotein in coronavirus strains, in restricting entry of the virus into cells in invitro studies.

During a virtual press conference, the company emphasised the use of their medicine for the prevention and treatment of Covid-19. Meanwhile, Sri Sri Ravishankar also announced that 10,000 doses of Kabasuraa Kudineer tablets would be donated to Delhi’s AYUSH Department for free distribution in light of the worsening coronavirus situation in the union territory. Dr Raj Manchanda, AYUSH Department, Delhi, said, “I am happy to receive the Kabasuraa Kudineer tablets for 10,000 people from Sri Sri Tattva for free distribution; we will be documenting the outcomes and share in due course.” According to data cited by Sri Sri Tattva, results showed significant improvement of clinical and laboratory parameters like immunity markers, viz. IFN-Β and IFN-Λ and antioxidant markers viz. Superoxide dismutase (SOD), Catalase (CAT), Malondialdehyde (MDA), Glutathione (GSH) after 14 days of treatment with Sri Sri Tattva immunity products along with standard of care.

Dr Ravi Reddy, Chief Science Officer, Sri Sri Tattva, told The Sunday Guardian: “Kabasuraa Kudineer is an immunity boosting medicine and an ancient Siddha formulation. It has shown an inhibitory role in SARS-COV-2 Spike: ACE2 interaction, in-vitro studies by FIZ at Frankfurt. This indicates that the medicine has the properties to ward off infection. Further studies are being enabled along these lines. Other research